Comparing Desferrioxamine and Light Fractionation Enhancement of ALA-PpIX Photodynamic Therapy in Skin Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Aug 31

PMID 27575852

Citations 23

Authors

Ana Luiza Ribeiro de Souza

Kayla Marra

Jason Gunn

Kimberley S Samkoe

Stephen Chad Kanick

Scott C Davis

M Shane Chapman

Edward V Maytin

Tayyaba Hasan

Brian W Pogue

Affiliations

Soon will be listed here.

Abstract

Background: Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis and squamous cell carcinoma, yet large response variations in effect are common between individuals. The aim of this study was to compare pre-treatment strategies that increase the therapeutic effect, including fractionated light delivery during PDT (fPDT) and use of iron chelator desferrioxamine (DFO), separately and combined.

Methods: Optical measurements of fluorescence were used to quantify PpIX produced, and the total amount of PpIX photobleached as an implicit measure of the photodynamic dose. In addition, measurements of white light reflectance were used to quantify changes in vascular physiology throughout the PDT treatment.

Results: fPDT produced both a replenishment of PpIX and vascular re-oxygenation during a 2 h dark interval between the first and second PDT light fractions. The absolute photodynamic dose was increased 57% by fPDT, DFO and their combination, as compared with PDT group (from 0.7 to 1.1). Despite that light fractionation increased oedema and scab formation during the week after treatment, no significant difference in long-term survival has been observed between treatment groups. However, outcomes stratified on the basis of measured photodynamic dose showed a significant difference in long-term survival.

Conclusions: The assessment of implicit photodynamic dose was a more significant predictor of efficacy for ALA-PDT skin cancer treatments than prescription of an enhanced treatment strategy, likely because of high individual variation in response between subjects.

Citing Articles

Noninvasive Ultra Low Intensity Light Photodynamic Treatment of Glioblastoma with Drug Augmentation: LoGlo PDT Regimen.

Kast R, Kast A, Arnhold J, Capanni F, Milla Sanabria L, Bader N Brain Sci. 2025; 14(12.

PMID: 39766363 PMC: 11674893. DOI: 10.3390/brainsci14121164.

Photosensitized Oxidative Damage from a New Perspective: The Influence of Before-Light and After-Light Reaction Conditions.

Lapoot L, Jabeen S, OConnor R, Korytowski W, Girotti A, Greer A J Org Chem. 2024; 89(18):12873-12885.

PMID: 39231123 PMC: 11421024. DOI: 10.1021/acs.joc.4c01305.

5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy.

Howley R, Chandratre S, Chen B Bioengineering (Basel). 2023; 10(4).

PMID: 37106683 PMC: 10136048. DOI: 10.3390/bioengineering10040496.

Photodynamic therapy with light-emitting diode arrays producing different light fields induces apoptosis and necrosis in gastrointestinal cancer.

Shi X, Yin H, Dong X, Li H, Li Y Front Oncol. 2023; 12:1062666.

PMID: 36591528 PMC: 9801516. DOI: 10.3389/fonc.2022.1062666.

Analysis of Renal Cell Carcinoma Cell Response to the Enhancement of 5-aminolevulinic Acid-mediated Protoporphyrin IX Fluorescence by Iron Chelator Deferoxamine.

Howley R, Mansi M, Shinde J, Restrepo J, Chen B Photochem Photobiol. 2022; 99(2):787-792.

PMID: 35857390 PMC: 10258817. DOI: 10.1111/php.13678.

References

Iinuma S, Farshi S, Ortel B, Hasan T . A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. Br J Cancer. 1994; 70(1):21-8. PMC: 2033301. DOI: 10.1038/bjc.1994.244. View

de Haas E, de Vijlder H, Sterenborg H, Neumann H, Robinson D . Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2007; 22(4):426-30. DOI: 10.1111/j.1468-3083.2007.02445.x. View

Gibbs S, Chen B, OHara J, Hoopes P, Hasan T, Pogue B . Protoporphyrin IX level correlates with number of mitochondria, but increase in production correlates with tumor cell size. Photochem Photobiol. 2006; 82(5):1334-41. DOI: 10.1562/2006-03-11-RA-843. View

Cairnduff F, Stringer M, Hudson E, Ash D, Brown S . Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer. 1994; 69(3):605-8. PMC: 1968847. DOI: 10.1038/bjc.1994.112. View

Henning J, Fournier R, Hampton J . A transient mathematical model of oxygen depletion during photodynamic therapy. Radiat Res. 1995; 142(2):221-6. View

Robinson D, de Bruijn H, Star W, Sterenborg H . Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol. 2003; 77(3):319-23. DOI: 10.1562/0031-8655(2003)077<0319:DATOTF>2.0.CO;2. View

Chang S, MacRobert A, Porter J, Bown S . The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. J Photochem Photobiol B. 1997; 38(2-3):114-22. DOI: 10.1016/s1011-1344(96)07441-6. View

de Campos Araujo L, Thomazine J, Lopez R . Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm. 2010; 75(1):48-55. DOI: 10.1016/j.ejpb.2010.01.008. View

Robinson D, de Bruijn H, de Wolf W, Sterenborg H, Star W . Topical 5-aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol. 2001; 72(6):794-802. DOI: 10.1562/0031-8655(2000)072<0794:TAAPTO>2.0.CO;2. View

10.

Choudry K, Brooke R, Farrar W, Rhodes L . The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 2003; 149(1):124-30. DOI: 10.1046/j.1365-2133.2003.05351.x. View

11.

de Bruijn H, van der Ploeg-van den Heuvel A, Sterenborg H, Robinson D . Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice: the influence of the dark interval. J Photochem Photobiol B. 2006; 85(3):184-90. DOI: 10.1016/j.jphotobiol.2006.07.004. View

12.

de Bruijn H, Kruijt B, van der Ploeg-van den Heuvel A, Sterenborg H, Robinson D . Increase in protoporphyrin IX after 5-aminolevulinic acid based photodynamic therapy is due to local re-synthesis. Photochem Photobiol Sci. 2007; 6(8):857-64. DOI: 10.1039/b703361c. View

13.

Middelburg T, de Vijlder H, de Bruijn H, van der Ploeg-van den Heuvel A, Neumann H, de Haas E . Topical photodynamic therapy using different porphyrin precursors leads to differences in vascular photosensitization and vascular damage in normal mouse skin. Photochem Photobiol. 2014; 90(4):896-902. DOI: 10.1111/php.12271. View

14.

Palm M, Goldman M . Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin. J Drugs Dermatol. 2011; 10(1):53-60. View

15.

Maytin E, Honari G, Khachemoune A, Taylor C, Ortel B, Pogue B . Vitamin D Combined with Aminolevulinate (ALA)-Mediated Photodynamic Therapy (PDT) for Human Psoriasis: A Proof-of-Principle Study. Isr J Chem. 2012; 52(8-9):767-775. PMC: 3526008. DOI: 10.1002/ijch.201200005. View

16.

Foster T, Murant R, Bryant R, Knox R, Gibson S, HILF R . Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res. 1991; 126(3):296-303. DOI: 10.2307/3577919. View

17.

Campbell S, Morton C, Alyahya R, Horton S, Pye A, Curnow A . Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol. 2008; 159(2):387-93. DOI: 10.1111/j.1365-2133.2008.08668.x. View

18.

Ibbotson S . An overview of topical photodynamic therapy in dermatology. Photodiagnosis Photodyn Ther. 2010; 7(1):16-23. DOI: 10.1016/j.pdpdt.2009.12.001. View

19.

Fang Y, Tsai Y, Wu P, Huang Y . Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm. 2008; 356(1-2):144-52. DOI: 10.1016/j.ijpharm.2008.01.020. View

20.

Curnow A, MacRobert A, Bown S . Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med. 2006; 38(4):325-31. DOI: 10.1002/lsm.20328. View